1-2 of 2
Jinyi Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin's Lymphoma

Lynda Groocock, Gauri Deb, Jinyi Zhu, Jim Gamez, Paola Castiglioni, Manuel Sanchez-Castillo, Justin Schumacher, Alicia Benitez Rondan, Diana Jankeel, Karla Martinez-Garcia, Scott Wood, Andy Christoforou, Carla Guarinos, Wei Zhang, Rama Krishna Narla, Christoph W. Zapf, Soraya Carrancio, Daniel W. Pierce, Mark Rolfe, Neil Bence, Antonia Lopez-Girona, Deborah S. Mortensen
Journal: Blood
Blood (2024) 144 (Supplement 1): 957.
https://doi.org/10.1182/blood-2024-210951
Published: 2024
Journal Articles

Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease

Emily Rychak, Goldie Yuan Lam Lui, Cristhian Fimbres, Christine Kim Kang, Younguk Sun, Sophie Peng, Jingjing Deng, Sarah Franc, Eugene Ciccimaro, Kimberly Peacock, Minerva Tran, Andy Christoforou, Jinyi Zhu, Geraldine Polido, Barbra Pagarigan, Scott Johnson, Faye Wang, Paula Katavolos, Bonny Gaffney, Estela Garcia, France Landry, Fletcher Paddison, Petia Shipkova, Hannah Powers, Giorgio Tamò, August Dietrich, Soraya Carrancio, Radha Ramakrishnan, Karen Augustine, Rama Krishna Narla, Thomas Cummins, Mark Rolfe, Neil Bence, Antonia Lopez-Girona
Journal: Blood
Blood (2024) 144 (Supplement 1): 169.
https://doi.org/10.1182/blood-2024-203653
Published: 2024